NorthWest EHealth (NWEH), a technology company based in the UK, has won three awards in the 2025 Pharmaceutical Technology Excellence Awards, in the Innovation, Safety, and Diversity categories, for making a transformative impact on clinical trial processes through its platforms, ConneXon and FARSITE.
The Pharmaceutical Technology Excellence Awards honor the most significant achievements and innovations in the pharmaceuticals industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies leading change and shaping the future of the industry.
Go deeper with GlobalData
NWEH have won the Innovation award for the ConneXon platform, which automates the reporting of Serious Adverse Events, significantly enhancing trial efficiency.
NWEH’s commitment to participant safety was acknowledged with the Safety award, thanks to ConneXon’s real-time monitoring capabilities that ensure swift interventions.
Finally, the Diversity award was granted for the FARSITE platform’s inclusive recruitment strategies, which promote socio-economic representation in clinical trials.
Automated reporting: Transforming clinical trials through ConneXon
NWEH’s ConneXon platform has redefined the landscape of clinical trials through its automated reporting capabilities. By automating the Serious Adverse Event (SAE) reporting process, ConneXon significantly reduces manual transcription errors and associated costs, achieving up to 70% savings in reporting expenses. The platform integrates real-time data from electronic health records (EHR), ensuring timely and precise safety monitoring, allowing research teams to focus on high-value tasks, accelerating study timelines and improving overall trial efficiency.
The ConneXon platform’s ability to automate SAE reporting not only reduces the administrative burden, but also improves the integrity of safety data by minimizing human error. ConneXon, thus, empowers clinical trial teams to allocate resources more effectively, leading to faster and more cost-effective trials.
Real-time monitoring capability enhances participant safety
Safety is paramount in clinical trials, and NWEH’s ConneXon platform excels in this domain by providing real-time safety monitoring. The platform’s ability to swiftly intervene in adverse events enhances participant safety and reduces human error through automation. By facilitating faster interventions and improving trial oversight, ConneXon sets a new standard for safety practices in clinical trials.
The platform’s operational efficiency further reduces the administrative burden on researchers, allowing them to focus on critical aspects of trial management. Real-time data integration ensures that adverse events are reported accurately and swiftly, reducing the risk of serious patient harm due to delays or inaccuracies. This proactive approach to safety monitoring not only enhances participant safety, but also improves the reliability of trial outcomes.
ConneXon’s real-time alerts and data integration capabilities enable medical monitors to recommend protocol amendments or take other proactive steps if needed, which ensures that participant safety is continuously prioritized.
Promoting diversity in clinical trials through inclusive recruitment strategies
NWEH’s FARSITE platform has made significant strides in promoting diversity within clinical trials. By integrating Deprivation Scores, FARSITE ensures diverse socio-economic representation, aligning with new regulatory guidelines. The integration of Deprivation Scores allows researchers to identify participants from diverse socio-economic backgrounds, including those from hard-to-reach or underrepresented groups. This capability ensures that clinical trials are inclusive and representative. By enhancing the generalisability of study results, FARSITE strengthens the platform’s commitment to improving equity and inclusivity in clinical research.
FARSITE’s targeted recruitment strategies support the inclusion of underrepresented groups, fostering community engagement and strengthening involvement in clinical research. By collaborating directly with General Practitioner (GP) practices, FARSITE streamlines participant recruitment, ensuring that only eligible participants are invited to join the study. This process enhances the accuracy and integrity of participant selection, reducing the risk of incorrect referrals.
“These awards highlight our dedication to bring market leading enhancements to our ConneXon and FARSITE Platforms. They are a testament to our continued impact, and the hard work and dedication from our team over the last year. Their commitment to transforming health data into meaningful insights that drive better patient outcomes, improve research efficiency, and promote diversity in clinical trials, is second to none. As we look to the future, we will continue to push the boundaries of data-driven healthcare innovation.”
– Jonathan Wogel, CEO, NWEH
Contact Details
NorthWest EHealth Ltd
2nd Floor Bright Building
Manchester Science Park
Pencroft Way
Manchester
United Kingdom
Company Profile
For over 15 years, NWEH has been at the forefront of transforming clinical trials, delivering measurable impact at every stage. We help to accelerate life-changing treatments to market through tech-driven platforms FARSITE and ConneXon, by harnessing real-world data, driving innovation and enhancing patient safety.
Links
Website: www.nweh.co.uk
